{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:37:06Z","timestamp":1789123026518,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404402"],"award-info":[{"award-number":["82404402"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["20224BAB206119"],"award-info":[{"award-number":["20224BAB206119"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009102","name":"Jiangxi Provincial Department of Education","doi-asserted-by":"publisher","award":["GJJ2201931"],"award-info":[{"award-number":["GJJ2201931"]}],"id":[{"id":"10.13039\/501100009102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejmech.2024.117200","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T12:59:52Z","timestamp":1735045192000},"page":"117200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Design, synthesis, and pharmacological evaluation of triazine-based PI3K\/mTOR inhibitors for the potential treatment of non-small cell lung cancer"],"prefix":"10.1016","volume":"284","author":[{"given":"Ming","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengze","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengzhao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3326-8380","authenticated-orcid":false,"given":"Shenxin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117200_bib1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117200_bib2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.117200_bib3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.117200_bib4","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2024.117200_bib5","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s12094-019-02075-1","article-title":"Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer","volume":"21","author":"Gao","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ejmech.2024.117200_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.trsl.2019.05.004","article-title":"Characterization of upregulated adhesion GPCRs in acute myeloid leukemia","volume":"212","author":"Yang","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejmech.2024.117200_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115620","article-title":"The mTOR signalling in corneal diseases: a recent update","volume":"213","author":"Li","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117200_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112820","article-title":"Research progress of mTOR inhibitors","volume":"208","author":"Chen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib9","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1172\/JCI95182","article-title":"Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K\/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells","volume":"127 6","author":"Kharas","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2024.117200_bib10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cell.2011.02.003","article-title":"Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase","volume":"144","author":"Sun","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.117200_bib11","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1021\/acs.jmedchem.8b01492","article-title":"Class 1 PI3K clinical candidates and recent inhibitor design strategies: a medicinal chemistry perspective","volume":"62","author":"Garces","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114971","article-title":"Recent advances in PI3K\/PKB\/mTOR inhibitors as new anticancer agents","volume":"246","author":"Occhiuzzi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cpt.2022.09.001","article-title":"PI3K\/AKT\/mTOR pathway, hypoxia, and glucose metabolism: potential targets to overcome radioresistance in small cell lung cancer","volume":"1","author":"Deng","year":"2023","journal-title":"Cancer Pathogenesis and Therapy"},{"key":"10.1016\/j.ejmech.2024.117200_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103749","article-title":"Prospects of targeting PI3K\/AKT\/mTOR pathway in pancreatic cancer","volume":"176","author":"Mortazavi","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2024.117200_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2021.10.010","article-title":"EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition","volume":"524","author":"Chen","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2024.117200_bib16","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer","volume":"28","author":"Jee","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.117200_bib17","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Genome Atlas Research, Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2024.117200_bib18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.117200_bib19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.117200_bib20","doi-asserted-by":"crossref","first-page":"17495","DOI":"10.1074\/jbc.M115.660498","article-title":"Signaling through the phosphatidylinositol 3-kinase (PI3K)\/Mammalian target of rapamycin (mTOR) Axis is responsible for aerobic glycolysis mediated by glucose transporter in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma","volume":"290","author":"Makinoshima","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib21","article-title":"Efficacy of PI3K\/AKT\/mTOR pathway inhibitors for the treatment of advanced solid cancers: a literature-based meta-analysis of 46 randomised control trials","volume":"13","author":"Li","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.117200_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116346","article-title":"Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition","volume":"46","author":"Yang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.canlet.2010.04.006","article-title":"Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells","volume":"296","author":"Kim","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2024.117200_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107123","article-title":"PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: clinical challenges and opportunities","volume":"202","author":"Liu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2024.117200_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.111055","article-title":"Targeting PI3K\/AKT\/mTOR signaling to overcome drug resistance in cancer","volume":"396","author":"Tufail","year":"2024","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2024.117200_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114055","article-title":"Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer","volume":"229","author":"Wu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib27","doi-asserted-by":"crossref","first-page":"17468","DOI":"10.1021\/acs.jmedchem.1c01674","article-title":"Design, synthesis, biological evaluation, and computational studies of novel fluorinated candidates as PI3K inhibitors: targeting fluorophilic binding sites","volume":"64","author":"Tantawy","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib28","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.1021\/acs.jmedchem.4c00173","article-title":"Design, synthesis, formulation, and bioevaluation of trisubstituted triazines as highly selective mTOR inhibitors for the treatment of human breast cancer","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib29","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1021\/acs.jmedchem.2c00549","article-title":"Discovery of novel phosphoinositide-3-kinase \u03b1 inhibitors with high selectivity, excellent bioavailability, and long-acting efficacy for gastric cancer","volume":"65","author":"Hou","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbcan.2018.09.001","article-title":"PI3K pathway in prostate cancer: all resistant roads lead to PI3K","volume":"1870","author":"Park","year":"2018","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2024.117200_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106728","article-title":"Discovery of potent and selective HPK1 inhibitors based on the 2,4-disubstituted pyrimidine scaffold with immune modulatory properties for ameliorating T cell exhaustion","volume":"139","author":"Zeng","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib32","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1039\/D2OB00582D","article-title":"The copper-catalyzed oxidation of arylmethyl triazines with H2O toward the oxidant-free synthesis of aroyl triazines","volume":"20","author":"Zeng","year":"2022","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib33","doi-asserted-by":"crossref","first-page":"20065","DOI":"10.1039\/D2NJ04417J","article-title":"Direct \u03b1-methylenation of triazines to terminal olefins with DMA","volume":"46","author":"Zeng","year":"2022","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib34","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.3390\/molecules28093676","article-title":"Ruthenium-catalyzed oxidative synthesis of N-(2-triazine)indoles by C-H activation","volume":"28","author":"Zeng","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.117200_bib35","doi-asserted-by":"crossref","first-page":"11905","DOI":"10.1039\/C8NJ02035C","article-title":"Ruthenium-catalyzed synthesis of 1,3,5-triazin-2(1H)-ones and dihydro[1,3,5]triazino[1,2-a]benzimidazoles from alcohols and guanides","volume":"42","author":"Zeng","year":"2018","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib36","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1039\/C8OB01397G","article-title":"Ruthenium-catalyzed synthesis of arylethyl 1,3,5-triazines from arylallyl alcohols and biguanides","volume":"16","author":"Zeng","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib37","doi-asserted-by":"crossref","first-page":"8225","DOI":"10.1039\/C6NJ01620K","article-title":"Ruthenium-catalyzed synthesis of tri-substituted 1,3,5-triazines from alcohols and biguanides","volume":"40","author":"Zeng","year":"2016","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib38","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1002\/ejoc.202000781","article-title":"Ruthenium catalyzed divergent alkylation and olefination of methyl 1,3,5-triazines with alcohols","volume":"2020","author":"Su","year":"2020","journal-title":"Eur. J. Org Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib40","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jm901830p","article-title":"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5\u2032-triphosphate competitive phosphatidylinositol-3-kinase\/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor","volume":"53","author":"Venkatesan","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112637","article-title":"Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K\/mTOR inhibitors","volume":"204","author":"Wu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib42","first-page":"1452","article-title":"Study on the stability of antitumor candidate gedatolisib in plasma in vitro and simulated gastric\/intestinal fluid and its catabolites analysis","volume":"31","author":"Wu","year":"2020","journal-title":"China Pharm."},{"key":"10.1016\/j.ejmech.2024.117200_bib39","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1021\/jm501778s","article-title":"Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2","volume":"58","author":"Pike","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib43","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/acs.jmedchem.9b01736","article-title":"Design, synthesis, and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3K\/mTOR dual inhibitors","volume":"63","author":"Yu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib44","doi-asserted-by":"crossref","first-page":"11121","DOI":"10.1021\/acs.jmedchem.0c01061","article-title":"Discovery and development of SPR519 as a potent, selective, and orally bioavailable inhibitor of PI3K\u03b1 and mTOR kinases for the treatment of solid tumors","volume":"63","author":"Mahajan","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib45","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1021\/jm9014394","article-title":"A series of \u03b1-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase II\u03b1 catalytic activity","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib46","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1021\/jm0495632","article-title":"1,3,4-Thiadiazole derivatives. Synthesis, structure elucidation, and Structure\u2212Antituberculosis activity relationship investigation","volume":"47","author":"Oru\u00e7","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib47","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.bmcl.2004.07.041","article-title":"Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor","volume":"14","author":"Heath","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.117200_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115241","article-title":"Synthesis of urea and thiourea derivatives of C20-epi-aminosalinomycin and their activity against Trypanosoma brucei","volume":"250","author":"Antoszczak","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116227","article-title":"Identification of 3-aryl-5-methyl-isoxazole-4-carboxamide derivatives and analogs as novel HIF-2\u03b1 agonists through docking-based virtual screening and structural modification","volume":"268","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib50","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.canlet.2014.02.025","article-title":"Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase\/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines","volume":"347","author":"Katanasaka","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2024.117200_bib51","first-page":"2316","article-title":"Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells : limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways","volume":"6","author":"Janmaat","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.117200_bib53","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1021\/acs.jmedchem.2c00040","article-title":"Novel sphingosine kinase 1 inhibitor suppresses growth of solid tumor and inhibits the lung metastasis of triple-negative breast cancer","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115618","article-title":"Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: a mini review","volume":"258","author":"El-Nassan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/BJ20111929","article-title":"Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1","volume":"444","author":"Schnute","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2024.117200_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116493","article-title":"Novel biaryloxazolidinone derivatives with broad-spectrum antibacterial activity, favorable drug-like profiles and in vivo efficacy against linezolid-resistant Staphylococcus aureus","volume":"273","author":"Duan","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117200_bib57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","article-title":"Suppression of insulin feedback enhances the efficacy of PI3K inhibitors","volume":"560","author":"Hopkins","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.117200_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116206","article-title":"Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody","volume":"267","author":"Zeng","year":"2024","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:07:19Z","timestamp":1762265239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424010821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":57,"alternative-id":["S0223523424010821"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117200","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and pharmacological evaluation of triazine-based PI3K\/mTOR inhibitors for the potential treatment of non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117200"}}